01—Abstract
Summary
Summary of the 8-K filed May 6, 2024. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals reported first quarter 2024 results on May 6, 2024, with product revenue of $2.69 billiona, up 13% year over year.
U.S. net product revenue rose 8% to $1.52 billionb and ex-U.S. revenue rose 21% to $1.17 billion, driven by TRIKAFTA/KAFTRIO uptake including younger patient label expansions. GAAP net income increased 57% to $1.10 billion ($4.21 diluted EPS) and non-GAAP net income rose 56% to $1.24 billion ($4.76 non-GAAP diluted EPS). Profit growth was supported by higher product revenue and lower acquired IPR&D expense, which fell from $347.1 million to $76.8 million.
Cash, cash equivalents and marketable securities reached $14.6 billionc, up from $13.7 billion at year-end 2023. Vertex reiterated full year 2024 guidance, including product revenue of $10.55 to $10.75 billion and combined non-GAAP R&D, acquired IPR&D and SG&A expenses of $4.3 to $4.4 billion. The company also highlighted regulatory progress: submissions for the vanzacaftor triple in cystic fibrosis to the FDA and EMA, a rolling NDA for suzetrigine in moderate-to-severe acute pain expected to complete in Q2 2024, and CASGEVY launches in several geographies.
The announced acquisition of Alpine Immune Sciences for approximately $4.9 billiond in cash, which adds povetacicept for IgA nephropathy, is expected to close in the second quarter of 2024. Investors should note that the press release's financial figures reflect a strong quarter, but the outlook depends on successful regulatory approvals, CASGEVY reimbursement and uptake, and the Alpine integration. The filing also notes that the Exhibit 99.1 press release is furnished rather than filed, so its content is not subject to Section 18 liability unless specifically incorporated into another filing.
02—Key points
Key Highlights
- Product revenue rose 13% to $2.69 billion, with U.S. up 8% to $1.52 billion and ex-U.S. up 21% to $1.17 billion.
- GAAP net income increased 57% to $1.10 billion, and non-GAAP net income increased 56% to $1.24 billion; diluted EPS was $4.21 GAAP and $4.76 non-GAAP.
- Full year 2024 product revenue guidance of $10.55 to $10.75 billion was reiterated, and non-GAAP operating expense guidance of $4.3 to $4.4 billion was unchanged.
- Acquired IPR&D expense fell to $76.8 million from $347.1 million, a major driver of the earnings improvement.
- Cash, cash equivalents and marketable securities increased to $14.6 billion from $13.7 billion at December 31, 2023.
- Vertex agreed to acquire Alpine Immune Sciences for about $4.9 billion in cash via a $65 per share tender offer, expected to close in Q2 2024.
- Regulatory milestones include vanzacaftor triple submissions to the FDA and EMA and a rolling NDA for suzetrigine, expected to be completed in Q2 2024.
03—Questions
Frequently Asked Questions
How did Vertex perform financially in Q1 2024?
Vertex reported product revenue of $2.69 billion, up 13% from Q1 2023. GAAP net income rose 57% to $1.10 billion, and non-GAAP net income rose 56% to $1.24 billion. Growth was driven by TRIKAFTA/KAFTRIO and lower acquired IPR&D expense.
Did Vertex change its full year 2024 guidance?
No. Vertex reiterated its full year 2024 guidance, including product revenue of $10.55 to $10.75 billion and combined non-GAAP R&D, acquired IPR&D and SG&A expenses of $4.3 to $4.4 billion. The non-GAAP effective tax rate guidance of 20% to 21% was also unchanged.
What is the Alpine Immune Sciences acquisition and when will it close?
Vertex agreed to acquire Alpine Immune Sciences for approximately $4.9 billion in cash, or $65 per share through a tender offer that commenced April 22, 2024. The deal is expected to close in Q2 2024. Alpine's lead asset, povetacicept, is a BAFF/APRIL dual antagonist in Phase 3-ready development for IgA nephropathy.
What drove the difference between GAAP and non-GAAP results?
The main adjustments were stock-based compensation of $191.9 million, intangible asset amortization of $5.0 million, and a $27.0 million decrease in the fair value of strategic investments. The GAAP effective tax rate was 14.0% versus a non-GAAP rate of 17.4%, largely due to a discrete adjustment to income tax reserves.
What are the key near-term catalysts for Vertex?
Key catalysts include FDA and EMA review of the vanzacaftor triple for cystic fibrosis, completion of the suzetrigine rolling NDA in Q2 2024, continued CASGEVY launch activity, and the Alpine acquisition closing in Q2 2024. Investors will also watch the June 2024 ADA data update for VX-880 in type 1 diabetes.
04—Continue